Stonepine Capital Management, LLC Buys BioDelivery Sciences International Inc, Melinta Therapeutics Inc, Oxford Immunotec Global PLC, Sells Amarin Corp PLC, BioSpecifics Technologies Corp, Vanda Pharmaceuticals Inc

• New Purchases: OXFD, OPNT, FOMX, KALV, SPRO, MTEM, ALDX, XENE, NEOS, SBPH,
• Added Positions: BDSI, MLNT, CDTX, OPHT, CTIC, CPIX,
• Reduced Positions: AMRN, BSTC, VNDA, CORV, HTGM, VIVE, CGIX, ATEC, CATB, NVLN,
• Sold Out: RIGL, ADMA, ACAD, SNDX, GEMP, CFMS, NVIV,

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonepine+Capital+Management%2C+LLC

1. Apollo Endosurgery Inc (APEN) - 2,577,996 shares, 11.61% of the total portfolio.
2. Amarin Corp PLC (AMRN) - 1,130,568 shares, 11.56% of the total portfolio. Shares reduced by 80.06%
3. BioSpecifics Technologies Corp (BSTC) - 285,259 shares, 10.48% of the total portfolio. Shares reduced by 38.16%
4. BioDelivery Sciences International Inc (BDSI) - 4,311,103 shares, 7.58% of the total portfolio. Shares added by 190.11%
5. CTI BioPharma Corp (CTIC) - 4,145,459 shares, 5.63% of the total portfolio. Shares added by 2.37%

Stonepine Capital Management, LLC initiated holding in Oxford Immunotec Global PLC. The purchase prices were between $11.87 and $17.64, with an estimated average price of $14.29. The stock is now traded at around $15.31. The impact to a portfolio due to this purchase was 2.3%. The holding were 225,877 shares as of 2018-09-30.

Stonepine Capital Management, LLC initiated holding in Opiant Pharmaceuticals Inc. The purchase prices were between $12.89 and $23.43, with an estimated average price of $17.33. The stock is now traded at around $15.77. The impact to a portfolio due to this purchase was 2.09%. The holding were 185,887 shares as of 2018-09-30.

Stonepine Capital Management, LLC initiated holding in Foamix Pharmaceuticals Ltd. The purchase prices were between $5.09 and $6.3, with an estimated average price of $5.71. The stock is now traded at around $3.97. The impact to a portfolio due to this purchase was 1.98%. The holding were 551,078 shares as of 2018-09-30.

Stonepine Capital Management, LLC initiated holding in KalVista Pharmaceuticals Inc. The purchase prices were between $8 and $22.11, with an estimated average price of $13.49. The stock is now traded at around $23.00. The impact to a portfolio due to this purchase was 1.92%. The holding were 138,100 shares as of 2018-09-30.

Stonepine Capital Management, LLC initiated holding in Spero Therapeutics Inc. The purchase prices were between $9.69 and $17.79, with an estimated average price of $11.67. The stock is now traded at around $8.26. The impact to a portfolio due to this purchase was 1.5%. The holding were 226,444 shares as of 2018-09-30.

Stonepine Capital Management, LLC initiated holding in Molecular Templates Inc. The purchase prices were between $4.07 and $6.25, with an estimated average price of $5.13. The stock is now traded at around $5.08. The impact to a portfolio due to this purchase was 1.28%. The holding were 378,295 shares as of 2018-09-30.

Stonepine Capital Management, LLC added to a holding in BioDelivery Sciences International Inc by 190.11%. The purchase prices were between $2.48 and $3, with an estimated average price of $2.81. The stock is now traded at around $3.59. The impact to a portfolio due to this purchase was 4.97%. The holding were 4,311,103 shares as of 2018-09-30.

Stonepine Capital Management, LLC added to a holding in Melinta Therapeutics Inc by 3652.10%. The purchase prices were between $3.9 and $6.75, with an estimated average price of $5.07. The stock is now traded at around $2.35. The impact to a portfolio due to this purchase was 4.73%. The holding were 1,958,595 shares as of 2018-09-30.

Stonepine Capital Management, LLC added to a holding in Cidara Therapeutics Inc by 54.20%. The purchase prices were between $3.7 and $5.25, with an estimated average price of $4.42. The stock is now traded at around $3.35. The impact to a portfolio due to this purchase was 0.64%. The holding were 656,148 shares as of 2018-09-30.

Stonepine Capital Management, LLC added to a holding in Ophthotech Corp by 21.59%. The purchase prices were between $2.31 and $2.83, with an estimated average price of $2.5. The stock is now traded at around $1.81. The impact to a portfolio due to this purchase was 0.61%. The holding were 2,324,782 shares as of 2018-09-30.

Stonepine Capital Management, LLC sold out a holding in Rigel Pharmaceuticals Inc. The sale prices were between $2.6 and $3.59, with an estimated average price of $3.01.

Stonepine Capital Management, LLC sold out a holding in ADMA Biologics Inc. The sale prices were between $4.39 and $6.85, with an estimated average price of $5.75.

Stonepine Capital Management, LLC sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $13.03 and $21.81, with an estimated average price of $15.72.

Stonepine Capital Management, LLC sold out a holding in Syndax Pharmaceuticals Inc. The sale prices were between $6.33 and $8.08, with an estimated average price of $7.14.

Stonepine Capital Management, LLC sold out a holding in Gemphire Therapeutics Inc. The sale prices were between $1.36 and $8.42, with an estimated average price of $4.23.

Stonepine Capital Management, LLC sold out a holding in Conformis Inc. The sale prices were between $0.89 and $1.28, with an estimated average price of $1.09.

Stonepine Capital Management, LLC reduced to a holding in Amarin Corp PLC by 80.06%. The sale prices were between $2.45 and $16.27, with an estimated average price of $3.75. The stock is now traded at around $17.14. The impact to a portfolio due to this sale was -8.53%. Stonepine Capital Management, LLC still held 1,130,568 shares as of 2018-09-30.

Stonepine Capital Management, LLC reduced to a holding in BioSpecifics Technologies Corp by 38.16%. The sale prices were between $44.14 and $61.16, with an estimated average price of $50.96. The stock is now traded at around $59.50. The impact to a portfolio due to this sale was -4.8%. Stonepine Capital Management, LLC still held 285,259 shares as of 2018-09-30.

Stonepine Capital Management, LLC reduced to a holding in Vanda Pharmaceuticals Inc by 45.9%. The sale prices were between $18.25 and $23, with an estimated average price of $20.38. The stock is now traded at around $23.43. The impact to a portfolio due to this sale was -3.19%. Stonepine Capital Management, LLC still held 324,600 shares as of 2018-09-30.

Stonepine Capital Management, LLC reduced to a holding in Correvio Pharma Corp by 53.46%. The sale prices were between $3.71 and $5.13, with an estimated average price of $4.4. The stock is now traded at around $3.46. The impact to a portfolio due to this sale was -2.37%. Stonepine Capital Management, LLC still held 898,157 shares as of 2018-09-30.

Stonepine Capital Management, LLC reduced to a holding in HTG Molecular Diagnostics Inc by 68.29%. The sale prices were between $2.8 and $5.34, with an estimated average price of $3.68. The stock is now traded at around $3.45. The impact to a portfolio due to this sale was -2.29%. Stonepine Capital Management, LLC still held 535,590 shares as of 2018-09-30.

Stonepine Capital Management, LLC reduced to a holding in Viveve Medical Inc by 32.47%. The sale prices were between $2.02 and $3.51, with an estimated average price of $2.84. The stock is now traded at around $2.18. The impact to a portfolio due to this sale was -2.07%. Stonepine Capital Management, LLC still held 2,599,711 shares as of 2018-09-30.